Abstract
Background: Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancerrelated deaths and its morbidity and mortality are increasing. PDAC patients have a very poor prognosis because of aggressive features of PDAC cells, shortage of reliable diagnostic biomarkers and deficiency of effective therapeutics.
Objective: The article aims to discuss the recent progress in the discovery of novel molecular targets and their related mechanisms in the invasion and metastasis of PDAC cells.
Methods: Literatures based on Pubmed database were searched and those related to the molecular targets involved in the invasion and metastasis of PDAC were reviewed.
Results: The most promising discovery of molecular targets and phenomena include epithelialmesenchymal transition (EMT), cancer stem cells (CSCs), metastasis-related genes, hypoxiainducible factors (HIFs), non-coding RNAs (ncRNAs) and L1 cell adhesion molecule (L1CAM), which contribute to the vital biological behaviors of PDAC cells and tumor microenvironments.
Conclusion: This review summarizes recent advances in novel molecular targets that regulate the invasion and metastasis of PDAC cells, and how they are targeted for developing diagnostic and therapeutic tools for combating PDAC. Further understanding the regulatory mechanisms of these molecular targets may help to discover biomarkers used for early diagnosis, predicting the prognosis and monitoring treatment response, and also to develop novel effective therapeutics.
Keywords: Pancreatic cancer, pancreatic ductal adenocarcinoma, invasion, metastasis, molecular targets, biomarkers.
Graphical Abstract
[2]
Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 2014; 74(11): 2913-21.
[3]
Akce M, Zaidi MY, Waller EK, El-Rayes BF, Lesinski GB. The potential of CAR T cell therapy in pancreatic cancer. Front Immunol 2018; 9: 2166.
[4]
Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet (London, England) 2011; 378(9791): 607-20.
[5]
Garrido-Laguna I, Hidalgo M. Pancreatic cancer: From state-of-the-art treatments to promising novel therapies. Nat Rev Clin Oncol 2015; 12(6): 319-34.
[7]
Noll EM, Eisen C, Stenzinger A, et al. CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma. Nat Med 2016; 22(3): 278-86.
[8]
McAllister SS, Weinberg RA. The tumour-induced systemic environment as a critical regulator of cancer progression and metastasis. Nat Cell Biol 2014; 16(8): 717-27.
[9]
Rhim AD, Mirek ET, Aiello NM, et al. EMT and dissemination precede pancreatic tumor formation. Cell 2012; 148(1-2): 349-61.
[10]
Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 2006; 7(2): 131-42.
[11]
Aiello NM, Brabletz T, Kang Y, Nieto MA, Weinberg RA, Stanger BZ. Upholding a role for EMT in pancreatic cancer metastasis. Nature 2017; 547(7661): E7-8.
[12]
Valastyan S, Weinberg RA. Tumor metastasis: Molecular insights and evolving paradigms. Cell 2011; 147(2): 275-92.
[13]
Wang Q, Qu C, Xie F, et al. Curcumin suppresses epithelial-to-mesenchymal transition and metastasis of pancreatic cancer cells by inhibiting cancer-associated fibroblasts. Am J Cancer Res 2017; 7(1): 125-33.
[14]
Reymond N, d’Agua BB, Ridley AJ. Crossing the endothelial barrier during metastasis. Nat Rev Cancer 2013; 13(12): 858-70.
[15]
Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009; 119(6): 1420-8.
[16]
Zeisberg M, Neilson EG. Biomarkers for epithelial-mesenchymal transitions. J Clin Invest 2009; 119(6): 1429-37.
[17]
Zhou P, Li B, Liu F, et al. The epithelial to mesenchymal transition (EMT) and cancer stem cells: Implication for treatment resistance in pancreatic cancer. Mol Cancer 2017; 16(1): 52.
[19]
David CJ, Huang YH, Chen M, et al. TGF-beta tumor suppression through a lethal EMT. Cell 2016; 164(5): 1015-30.
[20]
Zheng X, Carstens JL, Kim J, et al. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature 2015; 527(7579): 525-30.
[21]
Krebs AM, Mitschke J, Lasierra Losada M, et al. The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer. Nat Cell Biol 2017; 19(5): 518-29.
[22]
Wellner U, Schubert J, Burk UC, et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol 2009; 11(12): 1487-95.
[23]
Gaianigo N, Melisi D, Carbone C. EMT and treatment resistance in pancreatic cancer. Cancers 2017; 9(9): 122.
[24]
De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer 2013; 13(2): 97-110.
[25]
Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 2014; 15(3): 178-96.
[26]
Beuran M, Negoi I, Paun S, et al. The epithelial to mesenchymal transition in pancreatic cancer: A systematic review. Pancreatology 2015; 15(3): 217-25.
[27]
Jiang JH, Liu C, Cheng H, et al. Epithelial-mesenchymal transition in pancreatic cancer: Is it a clinically significant factor? Biochimica et biophysica acta 2015; 1855(1): 43-9.
[28]
Xie D, Cui J, Xia T, et al. Hippo transducer TAZ promotes epithelial mesenchymal transition and supports pancreatic cancer progression. Oncotarget 2015; 6(34): 35949-63.
[29]
Satoh K, Hamada S, Shimosegawa T. Involvement of epithelial to mesenchymal transition in the development of pancreatic ductal adenocarcinoma. J Gastroenterol 2015; 50(2): 140-6.
[31]
Ishiwata T. Cancer stem cells and epithelial-mesenchymal transition: Novel therapeutic targets for cancer. Pathol Int 2016; 66(11): 601-8.
[32]
Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3(7): 730-7.
[33]
Sreepadmanabh M, Toley BJ. Investigations into the cancer stem cell niche using in-vitro 3-D tumor models and microfluidics. Biotechnol Adv 2018; 36(4): 1094-110.
[34]
Li C, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. Cancer Res 2007; 67(3): 1030-7.
[35]
Giovannetti E, van der Borden CL, Frampton AE, Ali A, Firuzi O, Peters GJ. Never let it go: Stopping key mechanisms underlying metastasis to fight pancreatic cancer. Semin Cancer Biol 2017; 44: 43-59.
[36]
Bao B, Azmi AS, Aboukameel A, et al. Pancreatic cancer stem-like cells display aggressive behavior mediated via activation of FoxQ1. J Biol Chem 2014; 289(21): 14520-33.
[37]
Skoda J, Hermanova M, Loja T, et al. Co-Expression of cancer stem cell markers corresponds to a pro-tumorigenic expression profile in pancreatic adenocarcinoma. PLoS One 2016; 11(7)e0159255
[38]
Hermann PC, Huber SL, Herrler T, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007; 1(3): 313-23.
[39]
Li X, Ma Q, Xu Q, et al. SDF-1/CXCR4 signaling induces pancreatic cancer cell invasion and epithelial-mesenchymal transition in vitro through non-canonical activation of Hedgehog pathway. Cancer Lett 2012; 322(2): 169-76.
[40]
Liu L, Salnikov AV, Bauer N, et al. Triptolide reverses hypoxia-induced epithelial-mesenchymal transition and stem-like features in pancreatic cancer by NF-kappaB downregulation. Int J Cancer 2014; 134(10): 2489-503.
[41]
Giordano A, Gao H, Anfossi S, et al. Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer. Mol Cancer Ther 2012; 11(11): 2526-34.
[42]
Preca BT, Bajdak K, Mock K, et al. A self-enforcing CD44s/ZEB1 feedback loop maintains EMT and stemness properties in cancer cells. Int J Cancer 2015; 137(11): 2566-77.
[43]
Waddell N, Pajic M, Patch AM, et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 2015; 518(7540): 495-501.
[44]
Integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell 2017; 32(2): 185-203.e113
[45]
Graham JS, Jamieson NB, Rulach R, Grimmond SM, Chang DK, Biankin AV. Pancreatic cancer genomics: Where can the science take us? Clin Genet 2015; 88(3): 213-9.
[46]
Bailey P, Chang DK, Nones K, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 2016; 531(7592): 47-52.
[47]
Hosoda W, Chianchiano P, Griffin JF, et al. Genetic analyses of isolated high-grade pancreatic intraepithelial neoplasia (HG-PanIN) reveal paucity of alterations in TP53 and SMAD4. J Pathol 2017; 242(1): 16-23.
[48]
Yuan P, He XH, Rong YF, et al. KRAS/NF-kappaB/YY1/miR-489 signaling axis controls pancreatic cancer metastasis. Cancer Res 2017; 77(1): 100-11.
[49]
Yang K, Li Y, Lian G, et al. KRAS promotes tumor metastasis and chemoresistance by repressing RKIP via the MAPK-ERK pathway in pancreatic cancer. Int J Cancer 2018; 142(11): 2323-34.
[50]
Mueller S, Engleitner T, Maresch R, et al. Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes. Nature 2018; 554(7690): 62-8.
[51]
Ventura A, Kirsch DG, McLaughlin ME, et al. Restoration of p53 function leads to tumour regression in vivo. Nature 2007; 445(7128): 661-5.
[52]
Xiang JF, Wang WQ, Liu L, et al. Mutant p53 determines pancreatic cancer poor prognosis to pancreatectomy through upregulation of cavin-1 in patients with preoperative serum CA19-9 >/= 1,000 U/mL. Sci Rep 2016; 6: 19222.
[53]
Weissmueller S, Manchado E, Saborowski M, et al. Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor beta signaling. Cell 2014; 157(2): 382-94.
[54]
Mello SS, Valente LJ, Raj N, et al. A p53 Super-tumor suppressor
reveals a tumor suppressive p53-Ptpn14-Yap axis in pancreatic
cancer. Cancer Cell 2017; 32(4): 460-73.e466
[55]
Wang JD, Jin K, Chen XY, Lv JQ, Ji KW. Clinicopathological significance of SMAD4 loss in pancreatic ductal adenocarcinomas: a systematic review and meta-analysis. Oncotarget 2017; 8(10): 16704-11.
[56]
Whittle MC, Izeradjene K, Rani PG, et al. RUNX3 Controls a metastatic switch in pancreatic ductal adenocarcinoma. Cell 2015; 161(6): 1345-60.
[57]
Campbell PJ, Yachida S, Mudie LJ, et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 2010; 467(7319): 1109-13.
[58]
Robinson DR, Wu YM, Lonigro RJ, et al. Integrative clinical genomics of metastatic cancer. Nature 2017; 548(7667): 297-303.
[59]
Yachida S, Jones S, Bozic I, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010; 467(7319): 1114-7.
[60]
Zhou B, Irwanto A, Guo YM, et al. Exome sequencing and digital PCR analyses reveal novel mutated genes related to the metastasis of pancreatic ductal adenocarcinoma. Cancer Biol Ther 2012; 13(10): 871-9.
[61]
Yachida S, White CM, Naito Y, et al. Clinical significance of the genetic landscape of pancreatic cancer and implications for identification of potential long-term survivors. Clin Cancer Res 2012; 18(22): 6339-47.
[62]
Makohon-Moore AP, Zhang M, Reiter JG, et al. Limited heterogeneity of known driver gene mutations among the metastases of individual patients with pancreatic cancer. Nat Genet 2017; 49(3): 358-66.
[63]
McDonald OG, Li X, Saunders T, et al. Epigenomic reprogramming during pancreatic cancer progression links anabolic glucose metabolism to distant metastasis. Nat Genet 2017; 49(3): 367-76.
[64]
Collisson EA, Maitra A. Pancreatic cancer genomics 2.0: Profiling metastases. Cancer Cell 2017; 31(3): 309-10.
[65]
Nagelkerke A, Bussink J, Rowan AE, Span PN. The mechanical microenvironment in cancer: How physics affects tumours. Semin Cancer Biol 2015; 35: 62-70.
[66]
Klemm F, Joyce JA. Microenvironmental regulation of therapeutic response in cancer. Trends Cell Biol 2015; 25(4): 198-213.
[67]
Triner D, Shah YM. Hypoxia-inducible factors: A central link between inflammation and cancer. J Clin Invest 2016; 126(10): 3689-98.
[68]
Yu T, Tang B, Sun X. Development of inhibitors targeting hypoxia-inducible factor 1 and 2 for cancer therapy. Yonsei Med J 2017; 58(3): 489-96.
[69]
Bertout JA, Patel SA, Simon MC. The impact of O2 availability on human cancer. Nat Rev Cancer 2008; 8(12): 967-75.
[70]
Keith B, Johnson RS, Simon MC. HIF1alpha and HIF2alpha: Sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer 2011; 12(1): 9-22.
[71]
Hoffmann AC, Mori R, Vallbohmer D, et al. High expression of HIF1a is a predictor of clinical outcome in patients with pancreatic ductal adenocarcinomas and correlated to PDGFA, VEGF, and bFGF. Neoplasia (New York, NY) 2008; 10(7): 674-9.
[72]
Zhao T, Gao S, Wang X, et al. Hypoxia-inducible factor-1alpha regulates chemotactic migration of pancreatic ductal adenocarcinoma cells through directly transactivating the CX3CR1 gene. PLoS One 2012; 7(8)e43399
[73]
Matsuo Y, Ding Q, Desaki R, et al. Hypoxia inducible factor-1 alpha plays a pivotal role in hepatic metastasis of pancreatic cancer: an immunohistochemical study. J Hepatobiliary Pancreat Sci 2014; 21(2): 105-12.
[74]
Zhao X, Gao S, Ren H, et al. Hypoxia-inducible factor-1 promotes pancreatic ductal adenocarcinoma invasion and metastasis by activating transcription of the actin-bundling protein fascin. Cancer Res 2014; 74(9): 2455-64.
[75]
Zhou X, Guo X, Chen M, Xie C, Jiang J. HIF-3alpha promotes metastatic phenotypes in pancreatic cancer by transcriptional regulation of the RhoC-ROCK1 signaling pathway. Mol Cancer Res 2018; 16(1): 124-34.
[76]
Koshiji M, Kageyama Y, Pete EA, Horikawa I, Barrett JC, Huang LE. HIF-1alpha induces cell cycle arrest by functionally counteracting Myc. EMBO J 2004; 23(9): 1949-56.
[77]
Gordan JD, Bertout JA, Hu CJ, Diehl JA, Simon MC. HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. Cancer Cell 2007; 11(4): 335-47.
[78]
Zhu S, He C, Deng S, et al. MiR-548an, transcriptionally downregulated by HIF1alpha/HDAC1, suppresses tumorigenesis of pancreatic cancer by targeting vimentin expression. Mol Cancer Ther 2016; 15(9): 2209-19.
[79]
Lei J, Ma J, Ma Q, et al. Hedgehog signaling regulates hypoxia induced epithelial to mesenchymal transition and invasion in pancreatic cancer cells via a ligand-independent manner. Mol Cancer 2013; 12: 66.
[80]
Zhang Q, Lou Y, Zhang J, et al. Hypoxia-inducible factor-2alpha promotes tumor progression and has crosstalk with Wnt/beta-catenin signaling in pancreatic cancer. Mol Cancer 2017; 16(1): 119.
[81]
Choi H, Chun YS, Kim TY, Park JW. HIF-2alpha enhances beta-catenin/TCF-driven transcription by interacting with beta-catenin. Cancer Res 2010; 70(24): 10101-11.
[82]
Kaidi A, Williams AC, Paraskeva C. Interaction between beta-catenin and HIF-1 promotes cellular adaptation to hypoxia. Nat Cell Biol 2007; 9(2): 210-7.
[83]
Bo H, Zhang S, Gao L, et al. Upregulation of Wnt5a promotes epithelial-to-mesenchymal transition and metastasis of pancreatic cancer cells. BMC Cancer 2013; 13: 496.
[84]
MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 2009; 17(1): 9-26.
[85]
Zhang Q, Bai X, Chen W, et al. Wnt/beta-catenin signaling enhances hypoxia-induced epithelial-mesenchymal transition in hepatocellular carcinoma via crosstalk with hif-1alpha signaling. Carcinogenesis 2013; 34(5): 962-73.
[86]
Yang J, Zhang X, Zhang Y, et al. HIF-2alpha promotes epithelial-mesenchymal transition through regulating Twist 2 binding to the promoter of E-cadherin in pancreatic cancer. J Exp Clin Cancer Res 2016; 35: 26.
[87]
Wang M, Chen MY, Guo XJ, Jiang JX. Expression and significance of HIF-1alpha and HIF-2alpha in pancreatic cancer. J Huazhong Univ Sci Technolog Med Sci 2015; 35(6): 874-9.
[88]
Anastasiadou E, Jacob LS, Slack FJ. Non-coding RNA networks in cancer. Nat Rev Cancer 2018; 18(1): 5-18.
[89]
Pan Y, Li C, Chen J, et al. The emerging roles of long noncoding RNA ROR (lincRNA-ROR) and its possible mechanisms in human cancers. Cell Physiol Biochem 2016; 40(1-2): 219-29.
[90]
Greither T, Grochola LF, Udelnow A, Lautenschlager C, Wurl P, Taubert H. Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. Int J Cancer 2010; 126(1): 73-80.
[91]
He H, Di Y, Liang M, et al. The microRNA-218 and ROBO-1 signaling axis correlates with the lymphatic metastasis of pancreatic cancer. Oncol Rep 2013; 30(2): 651-8.
[92]
Jiao LR, Frampton AE, Jacob J, et al. MicroRNAs targeting oncogenes are down-regulated in pancreatic malignant transformation from benign tumors. PLoS One 2012; 7(2)e32068
[93]
Kent OA, Fox-Talbot K, Halushka MK. RREB1 repressed miR-143/145 modulates KRAS signaling through downregulation of multiple targets. Oncogene 2013; 32(20): 2576-85.
[94]
Kulshreshtha R, Ferracin M, Wojcik SE, et al. A microRNA signature of hypoxia. Mol Cell Biol 2007; 27(5): 1859-67.
[95]
Liu C, Cheng H, Shi S, et al. MicroRNA-34b inhibits pancreatic cancer metastasis through repressing Smad3. Curr Mol Med 2013; 13(4): 467-78.
[96]
Ma Y, Yu S, Zhao W, Lu Z, Chen J. miR-27a regulates the growth, colony formation and migration of pancreatic cancer cells by targeting Sprouty2. Cancer Lett 2010; 298(2): 150-8.
[97]
Mees ST, Mardin WA, Sielker S, et al. Involvement of CD40 targeting miR-224 and miR-486 on the progression of pancreatic ductal adenocarcinomas. Ann Surg Oncol 2009; 16(8): 2339-50.
[98]
Park JK, Henry JC, Jiang J, et al. miR-132 and miR-212 are increased in pancreatic cancer and target the retinoblastoma tumor suppressor. Biochem Biophys Res Commun 2011; 406(4): 518-23.
[99]
Sun Y, Zhang T, Wang C, et al. MiRNA-615-5p functions as a tumor suppressor in pancreatic ductal adenocarcinoma by targeting AKT2. PLoS One 2015; 10(4)e0119783
[100]
Sureban SM, May R, Lightfoot SA, et al. DCAMKL-1 regulates epithelial-mesenchymal transition in human pancreatic cells through a miR-200a-dependent mechanism. Cancer Res 2011; 71(6): 2328-38.
[101]
Tsuda N, Ishiyama S, Li Y, Ioannides CG, Abbruzzese JL, Chang DZ. Synthetic microRNA designed to target glioma-associated antigen 1 transcription factor inhibits division and induces late apoptosis in pancreatic tumor cells. Clin Cancer Res 2006; 12(21): 6557-64.
[102]
Wang C, Liu P, Wu H, et al. MicroRNA-323-3p inhibits cell invasion and metastasis in pancreatic ductal adenocarcinoma via direct suppression of SMAD2 and SMAD3. Oncotarget 2016; 7(12): 14912-24.
[103]
Wang P, Chen L, Zhang J, et al. Methylation-mediated silencing of the miR-124 genes facilitates pancreatic cancer progression and metastasis by targeting Rac1. Oncogene 2014; 33(4): 514-24.
[104]
Weiss FU, Marques IJ, Woltering JM, et al. Retinoic acid receptor antagonists inhibit miR-10a expression and block metastatic behavior of pancreatic cancer. Gastroenterology 2009; 137(6): 2136-45.
[105]
Yu S, Lu Z, Liu C, et al. miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer. Cancer Res 2010; 70(14): 6015-25.
[106]
Zhan Q, Fang Y, Deng X, et al. The interplay between miR-148a and DNMT1 might be exploited for pancreatic cancer therapy. Cancer Invest 2015; 33(7): 267-75.
[107]
Zhang L, Wang C, Yu S, et al. Loss of ARID1A expression correlates with tumor differentiation and tumor progression stage in pancreatic ductal adenocarcinoma. Technol Cancer Res Treat 2018; 171533034618754475
[108]
Zhao G, Wang B, Liu Y, et al. miRNA-141, downregulated in pancreatic cancer, inhibits cell proliferation and invasion by directly targeting MAP4K4. Mol Cancer Ther 2013; 12(11): 2569-80.
[109]
Zhao G, Zhang JG, Liu Y, et al. miR-148b functions as a tumor suppressor in pancreatic cancer by targeting AMPKalpha1. Mol Cancer Ther 2013; 12(1): 83-93.
[110]
Zhu Z, Xu Y, Zhao J, et al. miR-367 promotes epithelial-to-mesenchymal transition and invasion of pancreatic ductal adenocarcinoma cells by targeting the Smad7-TGF-beta signalling pathway. Br J Cancer 2015; 112(8): 1367-75.
[111]
Zou Y, Li J, Chen Z, et al. miR-29c suppresses pancreatic cancer liver metastasis in an orthotopic implantation model in nude mice and affects survival in pancreatic cancer patients. Carcinogenesis 2015; 36(6): 676-84.
[112]
Deng S, Li X, Niu Y, et al. MiR-652 inhibits acidic microenvironment-induced epithelial-mesenchymal transition of pancreatic cancer cells by targeting ZEB1. Oncotarget 2015; 6(37): 39661-75.
[113]
Liu YA, Zhang Y, Zheng Z, et al. MicroRNA-216b reduces growth, migration and invasion of pancreatic ductal adenocarcinoma cells by directly targeting rho-associated coiled-coil containing protein kinase 1. Oncol Lett 2018; 15(5): 6745-51.
[114]
Li Y, Vandenboom TG II, Wang Z, et al. miR-146a suppresses invasion of pancreatic cancer cells. Cancer Res 2010; 70(4): 1486-95.
[115]
Li D, Li X, Cao W, Qi Y, Yang X. Antagonism of microRNA-99a promotes cell invasion and down-regulates E-cadherin expression in pancreatic cancer cells by regulating mammalian target of rapamycin. Acta Histochem 2014; 116(5): 723-9.
[116]
Cao Z, Zheng SL, Yang G, et al. Correlation between miR-1178 expression and clinicopathological significance in human pancreatic cancer. Zhonghua Wai Ke Za Zhi 2017; 55(6): 468-73.
[117]
Zhang Y, Yang J, Cui X, et al. A novel epigenetic CREB-miR-373 axis mediates ZIP4-induced pancreatic cancer growth. EMBO Mol Med 2013; 5(9): 1322-34.
[118]
Ulitsky I. Evolution to the rescue: Using comparative genomics to understand long non-coding RNAs. Nat Rev Genet 2016; 17(10): 601-14.
[119]
Chandra GS, Nandan TY. Potential of long non-coding RNAs in cancer patients: From biomarkers to therapeutic targets. Int J Cancer 2017; 140(9): 1955-67.
[120]
Huang X, Zhi X, Gao Y, Ta N, Jiang H, Zheng J. LncRNAs in pancreatic cancer. Oncotarget 2016; 7(35): 57379-90.
[121]
An Y, Chen XM, Yang Y, et al. LncRNA DLX6-AS1 promoted cancer cell proliferation and invasion by attenuating the endogenous function of miR-181b in pancreatic cancer. Cancer Cell Int 2018; 18: 143.
[122]
Chen S, Zhang JQ, Chen JZ, et al. The over expression of long non-coding RNA ANRIL promotes epithelial-mesenchymal transition by activating the ATM-E2F1 signaling pathway in pancreatic cancer: An in vivo and in vitro study. Int J Biol Macromol 2017; 102: 718-28.
[123]
Fan Y, Shen B, Tan M, et al. TGF-beta-induced upregulation of malat1 promotes bladder cancer metastasis by associating with suz12. Clin Cancer Res 2014; 20(6): 1531-41.
[124]
Huang W, Li N, Hu J, Wang L. Inhibitory effect of RNA-mediated knockdown of zinc finger protein 91 pseudogene on pancreatic cancer cell growth and invasion. Oncol Lett 2016; 12(2): 1343-8.
[125]
Kim K, Jutooru I, Chadalapaka G, et al. HOTAIR is a negative prognostic factor and exhibits pro-oncogenic activity in pancreatic cancer. Oncogene 32(13) 2013; : 1616-25.
[126]
Li DD, Fu ZQ, Lin Q, et al. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma. World J Gastroenterol 2015; 21(31): 9348-57.
[127]
Liu B, Wu S, Ma J, et al. lncRNA GAS5 Reverses EMT and tumor stem cell-mediated gemcitabine resistance and metastasis by targeting miR-221/SOCS3 in pancreatic cancer. Mol Ther Nucleic Acids 2018; 13: 472-82.
[128]
Peng W, Gao W, Feng J. Long noncoding RNA HULC is a novel biomarker of poor prognosis in patients with pancreatic cancer. Med Oncol 2014; 31(12): 346.
[129]
Tian C, Jin Y, Shi S. Long non-coding RNA SUMO1P3 may promote cell proliferation, migration, and invasion of pancreatic cancer via EMT signaling pathway. Oncol Lett 2018; 16(5): 6109-15.
[130]
Wang X, Li H, Lu X, et al. Melittin-induced long non-coding RNA NONHSAT105177 inhibits proliferation and migration of pancreatic ductal adenocarcinoma. Cell Death & Dis 2018; 9(10): 940.
[131]
Yu Q, Zhou X, Xia Q, et al. Long non-coding RNA CCAT1 that can be activated by c-Myc promotes pancreatic cancer cell proliferation and migration. Am J Transl Res 2016; 8(12): 5444-54.
[132]
Yuan Q, Zhang Y, Feng L, Jiang Y. Upregulated long noncoding RNA LINC01296 indicates a dismal prognosis for pancreatic ductal adenocarcinoma and promotes cell metastatic properties by affecting EMT. J Cell Biochem 2019; 120(1): 552-61.
[133]
Zhan HX, Wang Y, Li C, et al. LincRNA-ROR promotes invasion, metastasis and tumor growth in pancreatic cancer through activating ZEB1 pathway. Cancer Lett 2016; 374(2): 261-71.
[134]
Zhang F, Li J, Xiao H, Zou Y, Liu Y, Huang W. AFAP1-AS1: A novel oncogenic long non-coding RNA in human cancers. Cell proliferation 2018; 51(1)
[135]
Zhou Y, Shan T, Ding W, et al. Study on mechanism about long noncoding RNA MALAT1 affecting pancreatic cancer by regulating Hippo-YAP signaling. J Cell Physiol 2018; 233(8): 5805-14.
[136]
Xiao H, Zhang F, Zou Y, Li J, Liu Y, Huang W. The function and mechanism of long non-coding RNA-ATB in cancers. Front Physiol 2018; 9: 321.
[137]
Fan YH, Ji CX, Xu B, Fan HY, Cheng ZJ, Zhu XG. Long noncoding RNA activated by TGF-beta in human cancers: A meta-analysis. Int J Clin Chem 2017; 468: 10-6.
[138]
Qu S, Yang X, Song W, et al. Downregulation of lncRNA-ATB correlates with clinical progression and unfavorable prognosis in pancreatic cancer. Tumour Biol 2016; 37(3): 3933-8.
[139]
Cheng Y, Jutooru I, Chadalapaka G, Corton JC, Safe S. The long non-coding RNA HOTTIP enhances pancreatic cancer cell proliferation, survival and migration. Oncotarget 2015; 6(13): 10840-52.
[140]
Fu Z, Chen C, Zhou Q, et al. LncRNA HOTTIP modulates cancer stem cell properties in human pancreatic cancer by regulating HOXA9. Cancer Lett 2017; 410: 68-81.
[141]
Chiu HS, Martinez MR, Bansal M, et al. High-throughput validation of ceRNA regulatory networks. BMC Genomics 2017; 18(1): 418.
[142]
Gao S, Wang P, Hua Y, et al. ROR functions as a ceRNA to regulate Nanog expression by sponging miR-145 and predicts poor prognosis in pancreatic cancer. Oncotarget 2016; 7(2): 1608-18.
[143]
Wang G, Pan J, Zhang L, Wei Y, Wang C. Long non-coding RNA CRNDE sponges miR-384 to promote proliferation and metastasis of pancreatic cancer cells through upregulating IRS1. Cell proliferation 2017; 50(6)
[144]
Zhao L, Kong H, Sun H, Chen Z, Chen B, Zhou M. LncRNA-PVT1 promotes pancreatic cancer cells proliferation and migration through acting as a molecular sponge to regulate miR-448. J Cell Physiol 2018; 233(5): 4044-55.
[145]
Gonzalez-Moreno O, Lecanda J, Green JE, et al. VEGF elicits epithelial-mesenchymal transition (EMT) in prostate intraepithelial neoplasia (PIN)-like cells via an autocrine loop. Exp Cell Res 2010; 316(4): 554-67.
[146]
Zhao X, Liu Y, Li Z, et al. Linc00511 acts as a competing endogenous RNA to regulate VEGFA expression through sponging hsa-miR-29b-3p in pancreatic ductal adenocarcinoma. J Cell Mol Med 2018; 22(1): 655-67.
[147]
Lund K, Dembinski JL, Solberg N, Urbanucci A, Mills IG, Krauss S. Slug-dependent upregulation of L1CAM is responsible for the increased invasion potential of pancreatic cancer cells following long-term 5-FU treatment. PLoS One 2015; 10(4)e0123684
[148]
Doberstein K, Harter PN, Haberkorn U, et al. Antibody therapy to human L1CAM in a transgenic mouse model blocks local tumor growth but induces EMT. Int J Cancer 2015; 136(5): E326-39.
[149]
Yu X, Yang F, Fu DL, Jin C. L1 cell adhesion molecule as a therapeutic target in cancer. Expert Rev Anticancer Ther 2016; 16(3): 359-71.
[150]
Zuo C, Hong Y, Qiu X, et al. Celecoxib suppresses proliferation and metastasis of pancreatic cancer cells by down-regulating STAT3 / NF-kB and L1CAM activities. Pancreatology 2018; 18(3): 328-33.
[151]
Ben Q, An W, Fei J, et al. Downregulation of L1CAM inhibits proliferation, invasion and arrests cell cycle progression in pancreatic cancer cells in vitro. Exp Ther Med 2014; 7(4): 785-90.
[152]
Magrini E, Villa A, Angiolini F, et al. Endothelial deficiency of L1 reduces tumor angiogenesis and promotes vessel normalization. J Clin Invest 2014; 124(10): 4335-50.
[153]
Geismann C, Arlt A, Bauer I, et al. Binding of the transcription factor Slug to the L1CAM promoter is essential for transforming growth factor-beta1 (TGF-beta)-induced L1CAM expression in human pancreatic ductal adenocarcinoma cells. Int J Oncol 2011; 38(1): 257-66.
[154]
Kiefel H, Bondong S, Pfeifer M, et al. EMT-associated up-regulation of L1CAM provides insights into L1CAM-mediated integrin signalling and NF-kappaB activation. Carcinogenesis 2012; 33(10): 1919-29.
[155]
Schafer H, Geismann C, Heneweer C, et al. Myofibroblast-induced tumorigenicity of pancreatic ductal epithelial cells is L1CAM dependent. Carcinogenesis 2012; 33(1): 84-93.
[156]
Roe JS, Hwang CI, Somerville TDD, et al. Enhancer reprogramming promotes pancreatic cancer metastasis. Cell 2017; 170(5): 875-88.
[157]
Hu B, Zhang K, Li S, et al. HIC1 attenuates invasion and metastasis by inhibiting the IL-6/STAT3 signalling pathway in human pancreatic cancer. Cancer Lett 2016; 376(2): 387-98.
[158]
Zhou B, Zhan H, Tin L, et al. TUFT1 regulates metastasis of pancreatic cancer through HIF1-Snail pathway induced epithelial-mesenchymal transition. Cancer Lett 2016; 382(1): 11-20.
[159]
Song Z, Feng C, Lu Y, Lin Y, Dong C. PHGDH is an independent prognosis marker and contributes cell proliferation, migration and invasion in human pancreatic cancer. Gene 2018; 642: 43-50.
[160]
Duan J, Li X, Huang S, et al. GOLPH2, a gene downstream of ras signaling, promotes the progression of pancreatic ductal adenocarcinoma. Mol Med Rep 2018; 17(3): 4187-94.
[161]
Saxena S, Hayashi Y, Wu L, et al. Pathological and functional significance of Semaphorin-5A in pancreatic cancer progression and metastasis. Oncotarget 2018; 9(5): 5931-43.
[162]
Kanteti R, Mirzapoiazova T, Riehm JJ, et al. Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma. Cancer Biol Ther 2018; 19(4): 316-27.
[163]
Suzuki K, Watanabe A, Araki K, et al. High STMN1 expression is associated with tumor differentiation and metastasis in clinical patients with pancreatic cancer. Anticancer Res 2018; 38(2): 939-44.
Related Books
Frontiers in Clinical Drug Research - Anti-Cancer Agents
NEOPLASIA and FERTILITY
Breast Cancer: Current Trends in Molecular Research
The Evolution of Radionanotargeting towards Clinical Precision Oncology: A Festschrift in Honor of Kalevi Kairemo
Nanotherapeutics for the Treatment of Hepatocellular Carcinoma
Topics in Anti-Cancer Research
Frontiers in Clinical Drug Research - Anti-Cancer Agents
Modern Cancer Therapies and Traditional Medicine: An Integrative Approach to Combat Cancers
Herbal Medicine: Back to the Future
Thrombosis in Cancer: A Medical Professional's Guide to Cancer Associated Thrombosis
Article Metrics
52
4
1
1